RT Journal Article
SR Electronic
T1 Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.29.21267006
DO 10.1101/2021.11.29.21267006
A1 Hall, Victoria
A1 Foulkes, Sarah
A1 Insalata, Ferdinando
A1 Saei, Ayoub
A1 Kirwan, Peter
A1 Atti, Ana
A1 Wellington, Edgar
A1 Khawam, Jameel
A1 Munro, Katie
A1 Cole, Michelle
A1 Tranquillini, Caio
A1 Taylor-Kerr, Andrew
A1 Hettiarachchi, Nipunadi
A1 Calbraith, Davina
A1 Sajedi, Noshin
A1 Milligan, Iain
A1 Themistocleous, Yrene
A1 Corrigan, Diane
A1 Cromey, Lisa
A1 Price, Lesley
A1 Stewart, Sally
A1 de Lacy, Elen
A1 Norman, Chris
A1 Linley, Ezra
A1 Otter, Ashley David
A1 Semper, Amanda
A1 Hewson, Jacqueline
A1 D’Arcangelo, Silvia
A1 ,
A1 Chand, Meera
A1 Brown, Colin S
A1 Brooks, Tim
A1 Islam, Jasmin
A1 Charlett, Andre
A1 Hopkins, Susan
YR 2021
UL http://medrxiv.org/content/early/2021/12/01/2021.11.29.21267006.abstract
AB Background Understanding the duration and effectiveness of infection and vaccine-acquired SARS-CoV-2 immunity is essential to inform pandemic policy interventions, including the timing of vaccine-boosters. We investigated this in our large prospective cohort of UK healthcare workers undergoing routine asymptomatic PCR testing.Methods We assessed vaccine effectiveness (VE) (up to 10-months after first dose) and infection-acquired immunity by comparing time to PCR-confirmed infection in vaccinated and unvaccinated individuals using a Cox regression-model, adjusted by prior SARS-CoV-2 infection status, vaccine-manufacturer/dosing-interval, demographics and workplace exposures.Results Of 35,768 participants, 27% (n=9,488) had a prior SARS-CoV-2 infection. Vaccine coverage was high: 97% had two-doses (79% BNT162b2 long-interval, 8% BNT162b2 short-interval, 8% ChAdOx1). There were 2,747 primary infections and 210 reinfections between 07/12/2020 and 21/09/2021. Adjusted VE (aVE) decreased from 81% (95% CI 68%-89%) 14-73 days after dose-2 to 46% (95% CI 22%-63%) >6-months; with no significant difference for short-interval BNT162b2 but significantly lower aVE (50% (95% CI 18%-70%) 14-73 days after dose-2 from ChAdOx1. Protection from infection-acquired immunity showed evidence of waning in unvaccinated follow-up but remained consistently over 90% in those who received two doses of vaccine, even in those infected over 15-months ago.Conclusion Two doses of BNT162b2 vaccination induce high short-term protection to SARS-CoV-2 infection, which wanes significantly after six months. Infection-acquired immunity boosted with vaccination remains high over a year after infection. Boosters will be essential to maintain protection in vaccinees who have not had primary infection to reduce infection and transmission in this population.Trial registration number ISRCTN11041050Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.medrxiv.org/content/10.1101/2020.12.15.20247981v1 Funding StatementThe study is funded by the Department for Health and Social Care and UKHSA (formerly PHE) with contributions from the governments of Northern Ireland, Scotland and Wales. Funding was also provided by The National Institute for Health Research (NIHR) as an Urgent Public Health Priority Study and through the Health Protection Research Units. The study was also awarded grant funding from the Medical Research Council (Grant title: Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was registered, number ISRCTN11041050, and received approval from the Berkshire Research Ethics Committee on 22 May 2020.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnnotated code for this analysis is available at: (https://github.com/SIREN-study/SARS-CoV-2-Immunity). The metadata for this analysis will be available to researchers through the Health Data Research UK CO-CONNECT platform and available for secondary analysis. https://github.com/SIREN-study/SARS-CoV-2-Immunity